Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023

Documenti analoghi

• Statin Drug‐Drug Interactions: Pharmacokinetic Basis of FDA Labeling Recommendations and Comparison Across Common Tertiary Clinical Resources
  di: James Mease, et al.
  Pubblicazione: (2024)
• Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment: Role and Opportunities
  di: Anuradha Ramamoorthy, et al.
  Pubblicazione: (2025)
• Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments
  di: Hiroe Kitagaki, et al.
  Pubblicazione: (2025)
• The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway
  di: Rajanikanth Madabushi, et al.
  Pubblicazione: (2024)
• Confirmatory Evidence Used in Non‐Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020–2023
  di: Bridget M. Nugent, et al.
  Pubblicazione: (2025)